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ABSTRACT 
The world population is increasing much faster. Many socio-economic conditions of people have also 
been adversely affected. Various side effects have been observed with modern contraceptive methods. 
In Ayurveda many contraceptive drugs are explained, According to Yoga-Ratnakar “Talispatra with 
Gairika” is considered as a potent contraceptive, hence to assess its clinical efficacy, Ovulatory effects, 
side effects of the formulation and to provide cost effective, safe and effective method of contraception 
and contribute to national health programme like family planning this study was under taken.  
Clinical study was conducted on 30 women, 15 in each group. In group I mixture of Talispatra (Taxus 
baccate) & Gairika (Red oxide) (10gm) a single dose was administered on 4th day of menstrual cycle 
with cold water. In group II tab Mala –D daily one administered from 5th day of M. C for 21 days, 
follicular study was done on 11th day of M. C. in each patient observed for 3 cycles.  
In clinical study test drug in group I had shown In Ist, IInd, IIIrd month Dominant Follicle observed in one 
woman (6. 66%), eight women (53. 33%), twelve woman (80%) respectively and endometrial thickness 
observed less than 7mm in ten women (66. 6%), 4 women (26. 66%) 3 women (80%) respectively the 
study drug shown, significant contraceptive activity in I month than II, III month and group II. But side 
effects were noted only in group II.  
Mixture of Talispatra & Gairika had shown significant contraceptive activity. It is effective, safe, 
acceptable, less expensive enough to obviate frequent administration & without medical supervision.  
KEYWORDS: Talispatra, Gairika, Mala-D, Follicullar study, Contraceptive activity. 
INTRODUCTION
Today there is pressing need for limiting the 
family size at a personal level and for the control of 
population at a national level with the increase in 
population it is obvious that serious problems loom ahead 
unless the number of our progeny is controlled3. The 
world population is increasing at much faster rate. Fertility 
control is very essential for maintaining satisfactory 
standards of living and for raising the existing standards in 
developing countries. A method or a system which allows 
intercourse and yet prevents conception is called a 
contraceptive method. Contraceptive measures may be 
used to avoid pregnancy entirely, to space pregnancies or 
to temporarily postpone pregnancy. 4Presently available 
Oral contraceptives like Mala-D, Mala-N, Ovral-L, Novelan 
may induce weight gain, nausea, headache, CA of Cx, CA of 
breast, certain neurologic and neuro-opthalmologic 
syndrome, candida vaginitis, trichomans vaginitis. 5 
Because of all these above side effects the basic 
expectations of woman are with contraception which is 
safe, effective, acceptable, less expensive, simple to 
administer, independent of coitus, long lasting enough to 
obviate frequent administration and requiring little or no 
medical supervision. Ayurvedic scholars have used safe, 
reliable contraceptives since many centuries. As a witness 
to this Yoga-Ratnakar (17th A. D) has mentioned the 
combination of Talispatra (Taxus Baccata) and Gairika 
(Red Oxide) taken in equal quantity and administered in a 
dose of 1 Karsha (10 grams) on 4th day of Rajakala 
(Menustrual cycle) with cold water as Anupan (Vehicle). 6 
The clinical study was conducted to assess the 
contraceptive effects of mixture of Talispatra and Gairika 
and to provide a non-toxic, safe oral contraceptive to the 
main stream of national health programme like family 
planning. This clinical study was carried out to assess the 
contraceptive effect of mixture of Talispatra and Gairika 
and to provide non toxic, safe oral contraceptive to the 
main stream of national health programme like family 
planning.  
MATERIALS AND METHODS 
 Thirty Women from both O. P. D. and I. P. D. of 
Banale nursing home, Gulbarga were included for the 
study. Mixture of Shodhita (Purified) Gairika & Talispatra 
churna, Mala-D, cold water and women (having child and 
regular menstrual cycle) formed the materials for clinical 
study. Shodhan (Purification) of Gairika & Talispatra 
churna were prepared in the practical pharmacy and used 
for this study.  
Sample Size: 30 Women were selected considering the 
inclusive and exclusive criteria& distributed 15 in each 
group.  
Inclusive Criteria 
1. Healthy women having the age between 22 years to 
40 years were selected.  
2. Women of child bearing age and possessing at least 
two children and 1-11/2 years after second child.  
3. The women those who were having regular 
menstrual cycle.  
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4. Women not desirous of having further child.  
5. Women having a child & voluntarily willing to take 
the drug, after taking proper consent.  
Exclusive Criteria 
1. Unhealthy women and age below 22 years & above 
40 years.  
2. Women suffering from anaemia, T. B., diabetes 
mellitus, ovarian cyst, fibroid etc.  
3. Unmarried, newly married women.  
4. Women having secondary amenorrhoea and other 
gynaecological disorders.  
5. Women those having irregular menstrual cycle.  
Methods: Clinical study was conducted in 2 groups, each 
containing 15 Women.  
1]. Group I (study group) Administration of mixture of S. 
Gairika (5 grams) + Talispatra churna (5 grams) with 
cold water on the 4th day of menstrual cycle, single dose, 
for only one cycle. (as per text Ref. )  
2]. Group II (standard group) Administration of Mala-D 1 
tablet daily from 5th day of menstrual cycle for a period of 
3 cycle. (as per drug schedule).  
Both groups were observed for 3 consecutive 
menstrual cycles. A detailed history was noted. Women 
were asked to come in between 11th to 13th day of 
menstrual cycle for follicular study for 4 consecutive 
cycles. Follicular study by Transvaginal Scan was done for 
4 consecutive cycles.  
Parameters 
    Follicular study Before T/T After T/T 
 - 11th to 13th day of menstrual cycle for 3 cycles.  
OBSERVATION AND RESULT 
Table no. 1 Following table shows change in appearance of the Dominant Follicle after treatment in group I (n=15) 
Sl. No.  Month No. of women in which 
Dominant Follicle appeared 
after T/T (%)  
No. of women in which 
Dominant Follicle did not 
appear after T/T (%)  
Statistical test 
applied 
P value 
1 First 1 (6. 66%)  14 (93. 32%)  χ2= 16. 607 HS 
P=0. 000 2 Second 8 (53. 33%)  7 (46. 66%)  
3 Third 12 (80%)  3 (20%)  
Table no. 2 shows change in the Endometrial thickness after treatment in group I (n=15) 
Sl. No.  Month No. of women in which 
endometrium is less than 7 
mm (%)  
No. of women in which 
endometrium is more than 7 
mm (%)  
Statistical test 
applied 
P value 
1 First 10 (66. 66%)  5 (33. 33%)  χ2= 8. 130 HS 
P=0. 017 2 Second 4 (26. 66%)  11 (73. 33%)  
3 Third 3 (20. 00%)  12 (80. 00%)  
Table no. 3 shows change in the appearance of Dominant Follicle before and after treatment in group II. 
Sl. No.  Appearance of dominant follicle Before 
treatment 
After treatment 
1st month 2nd month 3rd month 
1 No. of women in which Dominant Follicle appeared 15 (100%)  0 (0%)  0 (0%)  0 (0%)  
2 No. of women in which Dominant Follicle not 
appeared 
0 (0%)  15 (100%)  15 (100%)  15 (100%)  
Table no. 4 shows change in the Endometrial thickness before and after treatment in group II. (n=15) 
Sl. No.  Endometrial thickness Before 
treatment 
After treatment 
1st month 2nd month 3rd month 
1 No. of women in which 
endometrial thickness is less 
than 7mm 
0 (0%)  15 (100%)  15 (100%)  15 (100%)  
2 No. of women in which 
endometrial thickness is 
more than 7mm 
15 (100%)  0 (0%)  0 (0%)  0 (0%)  
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Graph-change in the appearance Graph-Change in the Endometrical of Dominant Follicle before and after 
thickness before and after treatment (Rx) in group I. (n=15) treatment (Rx) in group I (n=15) 
 
Graph -Change in the appearance of Graph - Change in the Endometrial Dominant Follicle before and after 
thickness before and after treatment (Rx) treatment (Rx) in group I (n=15) in group II. (n=15) 
 
DISCUSSION 
 The combination of Shodhita Gairika and 
Talispatra churna was administered with cold water on 
the 4th day of menstrual cycle acts as a contraceptive, has 
been explained in Yoga-Ratnakar. Hence an attempt was 
made in this clinical study to assess the contraceptive 
effect of the formulation. 30 women were selected 
considering inclusive and exclusive criteria during the 
period from June 2007 to August 2008. Detail history, 
clinical examination of the women was conducted. All the 
women were asked to come on 11th-13th day of menstrual 
cycle before the administration of drug for follicular study 
by Transvaginal Scan (TVS) for confirmation of Ovulatory 
cycles & to rule out pathological disorders in group I, 
mixture of Talispatra and Gairika (10 gm) administered on 
4th day of menstrual cycle with cold water single dose in 
one cycle only. In group II, 15 women were selected and 
Mala-D one tablet daily administered from 5th day of 
menstrual cycle 21 days for 3 cycles and asked them to 
come on 11th -13th day of menstrual cycle for follicular 
study by Transvaginal scan for 3 cycles.  
In Group I: Before the drug administration it was noted by 
transvaginal scan that 15 women had dominant follicle and 
endometrium thickness was more than 7mm. Then 
mixture of Talispatra and Gairika (10gm) was 
administered on 4th day of menstrual cycle, single dose and 
observed for 3 consecutive menstrual cycles without 
administration of this test drug or any other contraceptive 
drug.  
 After the drug administration on 4th day of 
menstrual cycle, 11th day the reports of tranvaginal scan in 
1st month it was noted that 14 women had no Dominant 
Follicle but in only one woman Dominant Follicle was 
observed. In 10 women endometrial hypoplasia was noted. 
No any other problems with their menses and other 
complications were noted.  
  Then again all the women were asked to come on 
11th – 13th day of menstrual cycle in second month without 
taking any contraceptive medicine and Follicular study 
was done by Transvaginal scan. In second month out of 15 
women Dominant Follicle appeared in 8 women and DF 
not appeared in 7 women and endometrial hypoplasia was 
noted in 4 women. None of the women had menstrual 
problem or any other complication.  
  Then again all the women were asked to come on 
11th-13th day of menstrual cycle in third month without 
taking any contraceptive medicine. Follicular study was 
done by TVS. In 3 women no Dominant Follicle but 12 
women had Dominant Follicle. In 12 women endometrial 
thickness was increased but in 3 women endometrial 
thickness was <7mm.  
 Statistical analysis was carried out by applying χ2 
test which shows χ2 = 16. 607 for Dominant Follicle 
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appearance and χ2 = 8. 130 for endometrial thickness. P 
values were calculated, which revealed p=0. 000 for 
Dominant Follicle and p= 0. 0017 for endometrial 
thickness which is highly significant.  
In Group II : Before the drug administration it was noted 
by transvaginal scan that 15 women had dominant follicle 
and endometrium thickness was more than 7mm. Then 
tablet Mala-D daily one was administered from 5th day of 
menstrual cycle, for 21 days for 3 menstrual cycles (every 
month) and observed for 3 consecutive cycle (with drug).  
After the drug administration Transvaginal scan 
done on 11th day of menstrual cycle in 1st, 2nd & 3rd months 
respectively. It was observed in follicular study by TVS that 
none of them had Dominant Follicle and endometrial 
thickness was not favorable for conception. It is expected 
with regular drug administration, once the drug is stopped 
the result will be like before treatment.  
 No any side effects were noted in study group I, 
while in standard group II some women had complaints of 
gastric irritation, burning chest and nausea etc.  
  As for as the probable mechanism of the action is 
concerned, Talispatra is having antiovulatory, anti-
implantation activity as well as it is uterine contractor. 
Antiovulatory activity is achieved may be due to the 
inhibition of ovulation and by producing endometrial 
hypoplasia. Inhibition of ovulation by preventing the 
release of ovum from ovary may achieved by blocking the 
pituitary secretion of gonadotropin which is necessary for 
ovulation. Oestrogen is necessary for maturation of follicle, 
the drug may be having anti-oestrogenic activity, it may act 
as an anti-oestrogenic by:- 1) Inhibition of oestrogen 
synthesis. 2) Due to Blockage of receptor binding.  
 Thus the release of gonadotropin releasing 
hormones from the hypothalamus may be prevented 
through the negative feedback mechanism, so there may 
be no sufficient release of FSH and LH from the anterior 
pituitary thus follicular growth may be inhibited. This 
activity may also disturb the estrogen androgen ratio. 
Collectively it may result into inhibition of maturation of 
follicle. In experimental study also histological study slides 
indicated suppressed of the maturation of graffian follicle, 
7 it may also provide the sound base for assessment of its 
anti-Ovulatory activity.  
 The study shows endometrial hypoplasia takes 
place, due to its anti-progestional activity. In experimental 
study it was proved that Talispatra & Gairika had anti-
implantation activity7, due to its anti progestinal activity. 
May be drug makes both the hormones to act 
synergistically on hypothalamo-pituitary axis, thus 
follicular growth may not initiated or if initiated 
recruitment does not occur. In this way inhibition of 
ovulation takes place.  
 Garbhashayasankocha takes place due to 
Tiktapradhana (Bitter, dominant) rasa of Talispatra and 
Kashaya rasa (astringent) of mixture of Talispatra and 
Gairika. This property of Sankocha (Contraction) may 
contribute more if taken with cold water. Gairika with 
Talispatra has demonstrated (Synergistic effect) 100% 
anti-implantation activity in albino rats. Based on this 
clinical study was undertaken7.  
 Gairika is red oxide of Iron, chemically the mineral 
is Fe2O3 corresponding to Fe 70% and Oxygen 30%. Iron is 
necessary for regulation of body temperature. It may 
prevent the increase of body temperature, necessary for 
ovulation and contributing in the anti-ovulatory activity 
along with Talispatra.  
  So due to its combined effect of anti-ovulatory, 
anti-implantation, uterine contractor it may acts as a 
contraceptive. Mixture of Talispatra and Gairika (10gm) 
shown significant contraceptive activity.  
 In the study it was observed that after 
administration of single dose anti-ovulatory effects were 
reversed gradually in II & III month indicating induction of 
functional sterility. So the drug may act as temporary 
contraceptive only not as permanent contraceptive.  
 All modern oral contraceptive drugs are suppose 
to consume daily for 21 days and recent some drugs are 
introduced twice in a week. But this Ayurvedic formulation 
can be consumed only once in a month gives significant 
contraceptive activity than modern drugs without any side 
effects.  
CONCLUSION 
 30 women formed the study population. 15 
women were administered mixture of Talispatra & Gairika 
with cold water on 4th day of menstrual cycle in group I. 15 
women were administered Tab. Mala-D at night daily from 
5th day of menstrual cycle in Group II. All the women were 
observed for a period of 3 cycles. Before the 
administration follicular study was done by transvaginal 
scan in group I & II. All women had dominant follicle and 
endometrial thickness was more than 7mm. Transvaginal 
scan was done on 11th – 13th day for 3 consecutive 
menstrual cycles.  
 In 1st month it was noted that in only one woman 
had Dominant Follicle But she had regular menstrual cycle. 
and 10 women had endometrial hypoplasia (less than 
7mm). In 2nd month in 7 women had Dominant Follicle & 
in 4 women had endometrial hypoplasia but all women 
had regular menstrual cycle.  
In 3rd month 4 women had Dominant Follicle & in 3 
women had endometrial hypoplasia, but they had regular 
menstrual cycle. In 20% women Dominant Follicle was not 
observed but endometrial hypoplasia was observed. Thus 
the study drug had shown significant contraceptive 
activity. 
At the 1st cycle 93. 33% & at the end of study in 
group I, 20% women had no Dominant Follicle & 
endometrial thickness was <7mm. In group I & II all the 
women had regular menstrual cycle indicating its 
contraceptive activity. Single dose of this Ayurvedic 
formulation shown significant contraceptive activity than 
modern contraceptive without any side effects, but 
gastritis, nausea, burning chest were noted in group II. The 
mixture of Talispatra with Gairika shown significant 
contraceptive activity and may contribute to the main 
stream of national health programme like family planning.  
 Due to its single dose the risk of forgetting pills 
leading to undesirable pregnancies was avoided. It does 
not require medical supervision and checkup. No any 
allergic manifestation appeared during study. During study 
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Dominant Follicle appeared in few women in 2nd and 3rd 
months indicating return of fertility, so it acts as a 
reversible and temporary method of contraception. The 
study drug is much cost effective, safe and effective 
method of contraception. It is a drug of choice for women 
who cannot tolerate oral pills, Intra-uterine devices and 
afraid of surgical aid. All modern oral contraceptive drugs 
are suppose to consume daily for 21 days and recent some 
drugs are introduced twice in a week. But this Ayurvedic 
formulation can be consumed only once in a month gives 
significant contraceptive activity than modern drugs 
without any side effect 
Scope for study 
 This study has given scope for a long period of drug 
administration on larger population to get still more 
clinical data.  
 This clinical study has given scope to think still more 
on new parameters like hormonal assay to prove its 
clinical efficacy, safety after longer period of drug 
administration.  
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